



JPA

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/789,562
		Filing Date	February 27, 2004
		First Named Inventor	Mitterer, Artur
		Art Unit	1653
		Examiner Name	NOT YET ASSIGNED
Total Number of Pages in This Submission		Attorney Docket Number	20695D-000120US


ENCLOSURES (Check all that apply)				
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)			
	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Return Postcard			
	Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual	Townsend and Townsend and Crew LLP Scott L Ausenhus		
Signature			
Date	05/27/04		

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Nicole Wartell		
Signature		Date	5/28/04

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


PATENT
Attorney Docket No.: 20695D-000120US
Client Reference No.: R-196.00 US



Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAY 28, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: 
Nicole Wartel

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Artur Mitterer et al.

Application No.: 10/789,562

Filed: February 27, 2004

For: A METHOD FOR PURIFYING
FACTOR VIII/VWF-COMPLEX BY
MEANS OF CATION EXCHANGE
CHROMATOGRAPHY

Examiner: NOT YET ASSIGNED

Art Unit: 1653

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. This application is a divisional of and relies upon U.S. Patent Application No. 09/367,459 for an earlier effective filing date under 35 U.S.C. §120. In accordance with 37 CFR §1.98(d), copies of those references that have been previously submitted to or cited by the Office in the parent application are not enclosed. In addition, U.S. patents which have not been previously submitted to or cited by the Office are not enclosed in accordance with the Patent Office waiver issued August 5, 2003 in the Official Gazette, which states as follows:

The Office hereby waives the requirement under 37 CFR §1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003. See 37 CFR §1.491(b).

In accordance with 37 CFR §1.98(a)(2), any copies of foreign patent references and non-patent literature references, which have not been previously cited, are enclosed.

Please note that some of the references cited are not in English but an English language equivalent is provided for these references as noted in the chart below and as noted on the form PTO/SB/08A.

<u>Document No.</u>	<u>Translation No.</u>
DE 35 04 385	US 4,578,218
EP 0 416 983	US 5,679,776
EP 0 705 846	US 5,869,617
EP 0 714 987	US 5,858,658
EP 0 714 988	US 5,789,153
WO 93/15199	US 5,876,969
WO 96/10584	US 5,854,403
WO 97/34930	US 6,228,613
WO 97/39033	US 6,307,032
WO 98/38219	US 6,465,624

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:nmb
60160962 v1



Substitute for form 1449A/P-1 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known	
			Application Number	10/789,562
			Filing Date	February 27, 2004
			First Named Inventor	Mitterer, Artur
			Art Unit	1653
			Examiner Name	NOT YET ASSIGNED
Sheet	1	of	2	Attorney Docket Number
			20695D-000120US	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-4,578,218	03-25-1986	Saundry et al.	
	A2	US-5,679,776	10-21-1997	Burnouf-Radosevich et al.	
	A3	US-5,789,153	08-04-1998	Falkner et al.	
	A4	US-5,854,403	12-29-1998	Fisher et al.	
	A5	US-5,858,658	01-12-1999	Haemmerle et al.	
	A6	US-5,869,617	02-09-1999	Fischer et al.	
	A7	US-5,876,969	03-02-1999	Fleer et al.	
	A8	US-5,877,152	03-02-1999	Fischer et al.	
	A9	US-5,880,265	03-09-1999	Fischer et al.	
	A10	US-6,103,693	08-15-2000	Fischer et al.	
	A11	US 6,228,613 B1	05-08-2001	Fischer et al.	
	A12	US-6,307,032 B1	10-23-2001	Schönhöfer et al.	
	A13	US-2002-0058625 A1	05-16-2002	Mitterer	
	A14	US-6,465,624 B1	10-15-2002	Fischer et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)		
	B1	AU	737986	B2	09-06-2001	
	B2	AU	744919	B2	09-18-1998	
	B3	CA	2,251,558		10-09-1998	
	B4	DE	35 04 385	A1	08-14-1985	English ~US-4,578,218
	B5	EP	0 131 740	B1	10-31-1985	
	B6	EP	0 295 645	A2	12-21-1988	
	B7	EP	0 416 983	B1	03-13-1991	
	B8	EP	0 600 480	A2	06-08-1994	
	B9	EP	0 705846	A1	10-04-1996	English ~US-5,869,617
	B10	EP	0 714 987	A2	06-05-1996	English ~US-5,858,658
	B11	EP	0 714 988	A2	06-05-1996	English ~US-5,789,153
	B12	PCT	WO 91/13093	A1	09-05-1991	
	B13	PCT	WO 93/15199	A1	08-05-1993	English ~US-5,876,969
	B14	PCT	WO 96/10584	A1	04-11-1996	English ~US-5,854,403
	B15	PCT	WO 97/34930		09-25-1997	English ~US-6,228,613
	B16	PCT	WO 97/39033		10-23-1997	English ~US-6,307,032
	B17	PCT	WO 98/38219		09-03-1998	English ~US-6,465,624
	B18	PCT	WO 98/38220	A1	09-03-1998	English ~AU 744919

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	2	of	2		
				Application Number	10/789,562
				Filing Date	February 27, 2004
				First Named Inventor	Mitterer, Artur
				Art Unit	1653
				Examiner Name	NOT YET ASSIGNED
				Attorney Docket Number	20695D-000120US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	BERNTORP, E.; Plasma Product Treatment in Various Types of von Willebrand's Disease"; <i>Haemostasis</i> ; 1994; pp. 289-297; Vol 24		
	C2	BOURGOIS, A. et al.; "Blood-coagulation Factor (vWF) Complex"; <i>Chem. Abs.</i> ; 1986; p. 380; Vol. 105; Abstract No. 178421n		
	C3	HARRISON, R.H., et al.; "Chromatography of the VIII/vWF Complex on Dextran Sulphate Sepharose"; <i>Trhomb. Res.</i> ; 1988; pp. 295-304; Vol. 50		
	C4	HARRISON, P., et al.; The Purification of the VIII/vWF Complex Using Dextran Sulfate Sepharose Chromatography"; <i>Chem. Abs.</i> ; 1990; p. 274; ; Vol. 112; Abstract No. 11822b		
	C5	KOOPS, et al.; "Immunoaffinity Purification of Factor VIII/von Willebrand Factor Complex"; <i>Chem Abs.</i> ; 1992; p. 324; Vol. 117; Abstract No. 3089f		
	C6	LETHAGEN, et al.; Pharmacokinetics and Hemostatic Effect of Different Factor VIII/von Willebrand Factor Concentrates in von Willebrand's Disease Type III"; <i>Ann. Hematol.</i> , 1992; pp. 253-259; Vol. 65		
	C7	MEJAN, O. et al.; "Immunopurification of Human Factor VIII/vWF Complex From Plasma; <i>Pharmaceuticals</i> ; 1983; p. 357; Vol. 109; Abstract No. 115910h.		
	C8	RUTTYN, Y. et al.; Chromatography of Human Plasma on Aminohexyl Sepharose: Separation of Factor VIII/vWF and Behavior of Factors II, VII, IX and X and Antithrombin III"; <i>Enzymes</i> ; 1989; p. 311; Vol. 111; Abstract No. 149359s.		
	C9	SAUNDRY et al.; "The Interaction of the Factor VIII/von Willebrand Factor Complex with Immobilized Metal Affinity Chromatography (IMAC) Matrixes"; <i>Biochem Methods</i> ; 1990; p. 252; ; Vol. 112; Abstract No. 18400w.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.